<table><tr><td rowspan="2">510(k) Owner:</td><td colspan="2">Alfa Wassermann Diagnostic Technologies, LLC</td><td rowspan="2"></td></tr><tr><td>Contact: Fax:</td><td>4 Henderson Drive West Caldwell, NJ 07006 Hkatz@AlfaWassermannUS.com Hyman Katz, Ph.D. Phone: 973-852-0158</td></tr><tr><td>Date Summary Prepared: Device:</td><td>May 14, 2013 Trade Name:</td><td>ACE BUN/Urea Reagent</td><td>973-852-0237</td></tr><tr><td></td><td colspan="3">Classification: Common/Classification Name:</td></tr><tr><td colspan="14"></td></tr><tr><td rowspan="9"></td><td rowspan="2">Classification:</td><td rowspan="2">Alkaline Picrate, Colorimetry, Creatinine (21 C.F.R. § 862.1225)</td><td>ACE Creatinine Reagent</td></tr><tr><td>Class 2</td></tr><tr><td colspan="3">Trade Name:</td></tr><tr><td colspan="3">Common/Classification Name:</td></tr><tr><td colspan="3">Product Code CGX</td></tr><tr><td colspan="3"></td></tr><tr><td colspan="3">Trade Name: ACE Uric Acid Reagent Classification: Class 1, reserved</td></tr><tr><td colspan="3">Common/Classification Name:</td></tr><tr><td colspan="3">Acid, Uric, Uricase (Colorimetric)</td></tr><tr><td colspan="3">(21 C.F.R. § 862.1775) Product Code KNK</td></tr><tr><td colspan="3"></td></tr><tr><td colspan="3"></td></tr><tr><td colspan="3">Trade Name: ACE CK Reagent</td></tr><tr><td colspan="3"></td></tr><tr><td colspan="3">Classification: Class 2</td></tr><tr><td colspan="3">Common/Classification Name: NAD Reduction/NADH Oxidation, CPK Or</td></tr><tr><td colspan="3">Isoenzymes</td></tr><tr><td colspan="3"></td></tr><tr><td colspan="3">(21 C.F.R. § 862.1215)</td></tr><tr><td colspan="3"></td></tr><tr><td colspan="3"></td></tr><tr><td colspan="3">Product Code CGS</td></tr><tr><td colspan="3"></td></tr><tr><td colspan="3"></td></tr><tr><td colspan="3"></td></tr><tr><td colspan="3"></td></tr><tr><td colspan="3"></td></tr><tr><td colspan="3"></td></tr><tr><td colspan="3"></td></tr><tr><td colspan="3"></td></tr><tr><td colspan="3"></td></tr><tr><td colspan="3"></td></tr><tr><td colspan="3"></td></tr><tr><td colspan="3"></td></tr><tr><td colspan="3"></td></tr><tr><td colspan="3"></td></tr><tr><td colspan="3"></td></tr></table>

<table><tr><td>Predicate Devices:</td><td>Alfa Wassermann ACE BUN/Urea Reagent, ACE Creatinine Reagent, ACE Uric Acid Reagent, and ACE CK Reagents (K930104)</td></tr><tr><td>Device Descriptions:</td><td>In the ACE BUN/Urea Reagent assay, urea in serum is hydrolyzed in the presence of urease to yield ammonia and carbon dioxide. The ammonia formed then reacts in the presence of glutamate dehydrogenase with 2-oxoglutarate and NADH to yield glutamate and NAD. NADH absorbs strongly at 340 nm, whereas NAD* does not. The initial rate of decrease in absorbance, monitored bichromatically at 340 nm/647 nm, is proportional to the urea concentration in the sample.</td></tr><tr><td></td><td>In the ACE Creatinine Reagent assay, creatinine reacts with picric acid in an alkaline medium to form a red-orange colored complex, which absorbs strongly at 505 nm. The rate of complex formation, determined by measuring the increase in absorbance bichromatically at 505 nm/573 nm during a fixed time interval, is directly proportional to the creatinine concentration in the sample. In the ACE Uric Acid Reagent assay, uric acid in serum is oxidized by uricase to allantoin and hydrogen peroxide. The hydrogen peroxide then acts to oxdatively couple dichlorohydroxybenzene sulfonic acid and 4-aminoantipyrine in a reaction catalyzed by</td></tr><tr><td></td><td>505 nm. The amount of chromogen formed is determined by measuring the increase in absorbance bichromatically at 505 nm/610 nm, and is directly proportional to the uric acid concentration in the sample. In the ACE CK Reagent assay, serum creatine kinase initiates the conversion of creatine phosphate to creatine with the transfer of a phosphate group to adenosine diphosphate (ADP), forming ATP. The ATP is then used in the phosphorylation of D-glucose to form D-glucose-6-phosphate and ADP. This reaction is catalyzed by hexokinase. The enzyme glucose-6-phosphate dehydrogenase catalyzes the reduction of D-glucose-6- phosphate and nicotinamide adenine dinucleotide phosphate (NADP†). The series of reactions triggered by serum creatine kinase and ending in the formation of NADPH. NADPH strongly absorbs at 340 nm, whereas NADP* does not. Therefore, the rate of</td></tr><tr><td>Intended Use:</td><td>Indications for Use: The ACE BUN/Urea Reagent is intended for the quantitative determination of blood urea nitrogen (BUN) concentration in serum and lithium heparin plasma using the ACE, ACE Alera, and ACE Axcel Clinical Chemistry Systems. BUN measurements are used in the diagnosis and treatment of certain renal and metabolic diseases. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only. The ACE Creatinine Reagent is intended for the quantitative determination of creatinine concentration in serum and lithium heparin plasma using the ACE, ACE Alera, and ACE Axcel Clinical Chemistry Systems. Creatinine measurements are used in the diagnosis and treatment of renal diseases, in monitoring renal dialysis, and as a calculation basis for measuring other urine analytes. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only. The ACE Uric Acid Reagent is intended for the quantitative determination of uric acid concentration in serum and lithium heparin plasma using the ACE, ACE Alera, and ACE Axcel Clinical Chemistry Systems. Uric acid measurements are used in the diagnosis and treatment of numerous renal and metabolic disorders, including renal failure, gout, leukemia, psoriasis, starvation or other wasting conditions and of patients</td></tr><tr><td rowspan="3">Technological Characteristics:</td><td>The ACE BUN/Urea Reagent consists of a single reagent bottle. The reagent contains α- ketoglutarate, urease, glutamate dehydrogenase, adenosine diphosphate (ADP), nicotinamide adenine dinucleotide and reduced (NADH). Acid.</td></tr><tr><td>The ACE Creatinine Reagent consists of two reagent bottles. The Sodium Hydroxide Reagent (R1) contains sodium hydroxide. The Picric Acid Reagent (R2) contains picric The ACE Uric Acid Reagent consists of a single reagent bottle. The reagent contains 4-</td></tr><tr><td>aminoantipyrine, dichlorohydroxybenzene sulfonic acid, peroxidase and uricase. The ACE CK Reagent consists of two reagent bottles. The Buffer Reagent (R1) contains: imidazole buffer, glucose, N-acetyl-cysteine, magnesium acetate, EDTA, NADP and hexokinase. The Substrate Reagent (R2) contains: creatine phosphate, ADP, AMP, diadenosine pentaphosphate, EDTA and glucose-6-phosphate dehydrogenase.</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Comparison of similarities and differences with predicatedeviceACE BUN/Urea Reagent</td></tr><tr><td rowspan=1 colspan=1>BUN/Urea</td><td rowspan=1 colspan=1>Candidate Device</td><td rowspan=1 colspan=1>Predicate DeviceK930104(ACE BUN/Urea)</td></tr><tr><td rowspan=1 colspan=1>Intended Use/Indications for Use</td><td rowspan=1 colspan=1>The ACE BUN/Urea Reagent is intended for thequantitative determination of blood urea nitrogen(BUN) concentration.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Platforms</td><td rowspan=1 colspan=1>ACE, ACE Alera®, and ACE Axcel Clinical ChemistrySystems</td><td rowspan=1 colspan=1>ACE ClinicalChemistry System</td></tr><tr><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>Photometric</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration Stability</td><td rowspan=1 colspan=1>7 days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>On-Board Stability</td><td rowspan=1 colspan=1>30 days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Serum and lithium heparin plasma</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=1>3μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reaction Volume</td><td rowspan=1 colspan=1>333 μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Expected Values</td><td rowspan=1 colspan=1>6 - 20 mg/dL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Measuring Range</td><td rowspan=1 colspan=1>3 - 100 mg/dL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Stability</td><td rowspan=1 colspan=1>Samples may be stored for 7 days at 4-8°C and for Iyear at -20 °C.</td><td rowspan=1 colspan=1>Same</td></tr></table>

# ACE Creatinine Reagent

Device Comparison with Predicate   

<table><tr><td rowspan=1 colspan=1>Creatinine</td><td rowspan=1 colspan=1>Candidate Device</td><td rowspan=1 colspan=1>Predicate DeviceK930104(ACE Creatinine)</td></tr><tr><td rowspan=1 colspan=1>Intended Use/Indications for Use</td><td rowspan=1 colspan=1>The ACE Creatinine Reagent is intended for thequantitative determination of creatinine concentration.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Platforms</td><td rowspan=1 colspan=1>ACE, ACE Alera®, and ACE Axcel ClinicalChemistry Systems</td><td rowspan=1 colspan=1>ACE ClinicalChemistry System</td></tr><tr><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>Photometric</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration Stability</td><td rowspan=1 colspan=1>2 days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>On-Board Stability</td><td rowspan=1 colspan=1>10 days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Serum and lithium heparin plasma</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=1>20 μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reaction Volume</td><td rowspan=1 colspan=1>240 μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Expected Values</td><td rowspan=1 colspan=1>Female: 0.6-1.1 mg/dLMale: 0.9-1.3 mg/dL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Measuring Range</td><td rowspan=1 colspan=1>0.33 - 25.0 mg/dL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Stability</td><td rowspan=1 colspan=1>Creatinine is stable for 7 days when refrigerated at 4-8°C and for 3 months frozen at -20°C.</td><td rowspan=1 colspan=1>Same</td></tr></table>

# ACE Uric Acid Reagent

<table><tr><td rowspan=1 colspan=1>Uric Acid</td><td rowspan=1 colspan=1>Candidate Device</td><td rowspan=1 colspan=1>Predicate DeviceK930104(ACE Uric Acid)</td></tr><tr><td rowspan=1 colspan=1>Intended Use/Indications for Use</td><td rowspan=1 colspan=1>The ACE CK Reagent is intended for the quantitativedetermination of creatine kinase activity.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Platforms</td><td rowspan=1 colspan=1>ACE, ACE Alera®, and ACE Axcel ClinicalChemistry Systems</td><td rowspan=1 colspan=1>ACE ClinicalChemistry System</td></tr><tr><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>Photometric</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration Stability</td><td rowspan=1 colspan=1>30 Days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>On-Board Stability</td><td rowspan=1 colspan=1>30 Days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Serum and lithium heparin plasma</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=1>3μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reaction Volume</td><td rowspan=1 colspan=1>243 μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Expected Values</td><td rowspan=1 colspan=1>Female: 2.6-6.0 mg/dLMale: 3.5-7.2 mg/dL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Measuring Range</td><td rowspan=1 colspan=1>1.5 - 16.0 mg/dL</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Sample Stability</td><td rowspan=1 colspan=1>Separated from cells, uric acid is stable for 3-5 days at4 °C and for 6 months frozen at -20°C.</td><td rowspan=1 colspan=1>Same</td></tr></table>

Device Comparison with Predicate   

<table><tr><td rowspan=1 colspan=3>ACE CK Reagent</td></tr><tr><td rowspan=1 colspan=1>Creatinine Kinase</td><td rowspan=1 colspan=1>Candidate Device</td><td rowspan=1 colspan=1>Predicate DeviceK930104(ACE CK)</td></tr><tr><td rowspan=1 colspan=1>Intended Use/Indications for Use</td><td rowspan=1 colspan=1>ACE Magnesium Reagent is intended for thequantitative determination of magnesium.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Platforms</td><td rowspan=1 colspan=1>ACE, ACE Alera*&quot;, and ACE Axcel ClinicalChemistry Systems</td><td rowspan=1 colspan=1>ACE ClinicalChemistry System</td></tr><tr><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>Photometric</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration Stability</td><td rowspan=1 colspan=1>Not Applicable</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>On-Board Stability</td><td rowspan=1 colspan=1>25 Days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Serum and lithium heparin plasma</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=1>5μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reaction Volume</td><td rowspan=1 colspan=1>170 μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Expected Values</td><td rowspan=1 colspan=1>Female: 26-140 U/LMale: 38-174 U/L</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Measuring Range</td><td rowspan=1 colspan=1>11 - 1350 U/L</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Sample Stability</td><td rowspan=1 colspan=1>Serum magnesium is stable for 7 days at 4-8°C and1 year at -20 °C if the serum is separated from theerythrocytes.</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td rowspan=9 colspan=1>PerformanceData:In-HousePrecision -Serum vs.Plasma</td><td rowspan=1 colspan=10>Performance data for the Alfa Wassermann ACE Reagents run on theAlfa Wassermann ACE, ACE Alera and ACE Axcel Clinical ChemistrySystemsIn-House Precision: Serum vs. Plasma - ACE BUN/Urea Reagent</td></tr><tr><td rowspan=1 colspan=10>Precision (SD, %CV)</td></tr><tr><td rowspan=1 colspan=1>BUNmg/dL</td><td rowspan=1 colspan=1>ACEMean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>AleraMean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>AxcelMean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>SerumLow</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0.5, 11.1%</td><td rowspan=1 colspan=1>0.6, 12.4%</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0.4. 7.9%</td><td rowspan=1 colspan=1>0.6, 13.6%</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0.4, 8.1%</td><td rowspan=1 colspan=1>0.5.12.1%</td></tr><tr><td rowspan=1 colspan=1>SerumMid</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>0.7, 1.4%</td><td rowspan=1 colspan=1>0.9, 1.8%</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>0.4,0.9%</td><td rowspan=1 colspan=1>0.7, 1.5%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0.6, 1.2%</td><td rowspan=1 colspan=1>0.7, 1.5%</td></tr><tr><td rowspan=1 colspan=1>SerumHigh</td><td rowspan=1 colspan=1>85</td><td rowspan=1 colspan=1>2.4,2.8%</td><td rowspan=1 colspan=1>2.7, 3.2%</td><td rowspan=1 colspan=1>85</td><td rowspan=1 colspan=1>1.4, 1.6%</td><td rowspan=1 colspan=1>1.8.2.1%</td><td rowspan=1 colspan=1>85</td><td rowspan=1 colspan=1>1.3, 1.5%</td><td rowspan=1 colspan=1>1.7.2.0%</td></tr><tr><td rowspan=1 colspan=1>PlasmaLow</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0.4, 10.7%</td><td rowspan=1 colspan=1>0.5. 12.8%</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0.0, 0.0%</td><td rowspan=1 colspan=1>0.0, 0.0%</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0.3,6.3%</td><td rowspan=1 colspan=1>0.3, 6.3%</td></tr><tr><td rowspan=1 colspan=1>PlasmaMid</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>0.4,0.9%</td><td rowspan=1 colspan=1>0.7, 1.5%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0.5, 1.1%</td><td rowspan=1 colspan=1>0.9, 1.9%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0.6, 1.4%</td><td rowspan=1 colspan=1>0.6, 1.4%</td></tr><tr><td rowspan=1 colspan=1>PlasmaHigh</td><td rowspan=1 colspan=1>85</td><td rowspan=1 colspan=1>2.9, 3.4%</td><td rowspan=1 colspan=1>3.2. 3.8%</td><td rowspan=1 colspan=1>85</td><td rowspan=1 colspan=1>1.3.1.5%</td><td rowspan=1 colspan=1>1.6. 1:9%</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>1.8, 2.2%</td><td rowspan=1 colspan=1>1.9,2.3%</td></tr></table>

In-House Precision: Serum vs. Plasma  ACE Creatinine Reagent   

<table><tr><td rowspan=1 colspan=10>Precision (SD, %CV)</td></tr><tr><td rowspan=1 colspan=1>Creatininemg/dL</td><td rowspan=1 colspan=1>ACEMean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>AleraMean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>AxcelMean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>SerumLow</td><td rowspan=1 colspan=1>0.67</td><td rowspan=1 colspan=1>0.04, 5.8%</td><td rowspan=1 colspan=1>0.06, 8.5%</td><td rowspan=1 colspan=1>0.70</td><td rowspan=1 colspan=1>0.02, 3.2%</td><td rowspan=1 colspan=1>0.04, 5.6%</td><td rowspan=1 colspan=1>0.70</td><td rowspan=1 colspan=1>0.04, 6.0%</td><td rowspan=1 colspan=1>0.06, 8.1%</td></tr><tr><td rowspan=1 colspan=1>SerumMid</td><td rowspan=1 colspan=1>9.32</td><td rowspan=1 colspan=1>0.28, 3.0%</td><td rowspan=1 colspan=1>0.28, 3.0%</td><td rowspan=1 colspan=1>9.24</td><td rowspan=1 colspan=1>0.21, 2.3%</td><td rowspan=1 colspan=1>0.22, 2.4%</td><td rowspan=1 colspan=1>9.31</td><td rowspan=1 colspan=1>0.16, 1.7%</td><td rowspan=1 colspan=1>0.19,2.1%</td></tr><tr><td rowspan=1 colspan=1>SerumHigh</td><td rowspan=1 colspan=1>.18.25</td><td rowspan=1 colspan=1>0.13, 0.7%</td><td rowspan=1 colspan=1>0.35, 1.9%</td><td rowspan=1 colspan=1>17.96</td><td rowspan=1 colspan=1>0.18, 1.0%</td><td rowspan=1 colspan=1>0.22, 1.2%</td><td rowspan=1 colspan=1>17.97</td><td rowspan=1 colspan=1>0.14,0.8%</td><td rowspan=1 colspan=1>0.23, 1.3%</td></tr><tr><td rowspan=1 colspan=1>PlasmaLow</td><td rowspan=1 colspan=1>0.65</td><td rowspan=1 colspan=1>0.04, 6.3%</td><td rowspan=1 colspan=1>0.06, 9.0%</td><td rowspan=1 colspan=1>0.66</td><td rowspan=1 colspan=1>0.04, 5.5%</td><td rowspan=1 colspan=1>0.05, 7.8%</td><td rowspan=1 colspan=1>0.64</td><td rowspan=1 colspan=1>0.04, 6.6%</td><td rowspan=1 colspan=1>0.06, 9.3%</td></tr><tr><td rowspan=1 colspan=1>PlasmaMid</td><td rowspan=1 colspan=1>9.47</td><td rowspan=1 colspan=1>0.23. 2.5%</td><td rowspan=1 colspan=1>0.25, 2.7%</td><td rowspan=1 colspan=1>9.41</td><td rowspan=1 colspan=1>0.23, 2.5%</td><td rowspan=1 colspan=1>0.23, 2.5%</td><td rowspan=1 colspan=1>9.42</td><td rowspan=1 colspan=1>0.19,2.0%</td><td rowspan=1 colspan=1>0.25, 2.6%</td></tr><tr><td rowspan=1 colspan=1>PlasmaHigh</td><td rowspan=1 colspan=1>18.38</td><td rowspan=1 colspan=1>0.20, 1.1%</td><td rowspan=1 colspan=1>0.45, 2.4%</td><td rowspan=1 colspan=1>18.04</td><td rowspan=1 colspan=1>0.19, 1.0%</td><td rowspan=1 colspan=1>0.22, 1.2%</td><td rowspan=1 colspan=1>18.13</td><td rowspan=1 colspan=1>0.31, 1.7%</td><td rowspan=1 colspan=1>0.43, 2.4%</td></tr></table>

Performance Data:

In-House Precision - Serum vs. Plasma

In-House Precision: Serum vs. Plasma  ACE Uric Acid Reagent   

<table><tr><td rowspan=1 colspan=10>Precision (SD, %CV)</td></tr><tr><td rowspan=1 colspan=1>Uric Acidmg/dL</td><td rowspan=1 colspan=1>ACEMean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>AleraMean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>AxcelMean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>SerumLow</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>0.1, 2.6%</td><td rowspan=1 colspan=1>0.2, 4.5%</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>0.1, 3.0%</td><td rowspan=1 colspan=1>0.2.4.6%</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>0.1, 1.5%</td><td rowspan=1 colspan=1>0.2. 4.4%</td></tr><tr><td rowspan=1 colspan=1>SerumMid</td><td rowspan=1 colspan=1>9.3</td><td rowspan=1 colspan=1>0.1, 1.3%</td><td rowspan=1 colspan=1>0.2, 2.5%</td><td rowspan=1 colspan=1>9.2</td><td rowspan=1 colspan=1>0.1, 0.8%</td><td rowspan=1 colspan=1>0.2, 2.6%</td><td rowspan=1 colspan=1>9.3</td><td rowspan=1 colspan=1>0.1, 0.9%</td><td rowspan=1 colspan=1>0.3.2.8%</td></tr><tr><td rowspan=1 colspan=1>SerumHigh</td><td rowspan=1 colspan=1>15.0</td><td rowspan=1 colspan=1>0.3, 1.8%</td><td rowspan=1 colspan=1>0.3, 2.0%</td><td rowspan=1 colspan=1>14.8</td><td rowspan=1 colspan=1>0.3, 1.9%</td><td rowspan=1 colspan=1>0.3, 2.1%</td><td rowspan=1 colspan=1>14.9</td><td rowspan=1 colspan=1>0.2, 1.1%</td><td rowspan=1 colspan=1>0.3, 1.8%</td></tr><tr><td rowspan=1 colspan=1>PlasmaLow</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>0.2, 3.6%</td><td rowspan=1 colspan=1>0.2.5.5%</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>0.1, 3.3%</td><td rowspan=1 colspan=1>0.2, 5.5%</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>0.1, 2.8%</td><td rowspan=1 colspan=1>0.2, 4.5%</td></tr><tr><td rowspan=1 colspan=1>PlasmaMid</td><td rowspan=1 colspan=1>9.0</td><td rowspan=1 colspan=1>0.1, 0.7%</td><td rowspan=1 colspan=1>0.2, 1.9%</td><td rowspan=1 colspan=1>8.9</td><td rowspan=1 colspan=1>0.2, 2.1%</td><td rowspan=1 colspan=1>0.2, 2.6%</td><td rowspan=1 colspan=1>9.0</td><td rowspan=1 colspan=1>0.1, 1.0%</td><td rowspan=1 colspan=1>0.2, 2.0%</td></tr><tr><td rowspan=1 colspan=1>PlasmaHigh</td><td rowspan=1 colspan=1>14.7</td><td rowspan=1 colspan=1>0.2, 1.2%</td><td rowspan=1 colspan=1>0.2, 1.4%</td><td rowspan=1 colspan=1>14.5</td><td rowspan=1 colspan=1>0.3, 1:8%</td><td rowspan=1 colspan=1>0.3, 1.9%</td><td rowspan=1 colspan=1>14.5</td><td rowspan=1 colspan=1>0.2, 1.2%</td><td rowspan=1 colspan=1>0.2, 1.3%</td></tr></table>

In-House Precision: Serum vs. Plasma - ACE CK Reagent   

<table><tr><td rowspan=1 colspan=10>Precision (SD, %CV)</td></tr><tr><td rowspan=1 colspan=1>CKmg/dL</td><td rowspan=1 colspan=1>ACEMean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>AleraMean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>AxcelMean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>SerumLow</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>3.2, 4.0%</td><td rowspan=1 colspan=1>3.2, 4.0%</td><td rowspan=1 colspan=1>81</td><td rowspan=1 colspan=1>3.8, 4.7%</td><td rowspan=1 colspan=1>4.1,5.0%</td><td rowspan=1 colspan=1>85</td><td rowspan=1 colspan=1>1.5.1.7%</td><td rowspan=1 colspan=1>2.3.2.7%</td></tr><tr><td rowspan=1 colspan=1>SerumMid</td><td rowspan=1 colspan=1>636</td><td rowspan=1 colspan=1>7.7, 1.2%</td><td rowspan=1 colspan=1>30.9, 4.9%</td><td rowspan=1 colspan=1>615</td><td rowspan=1 colspan=1>9.4, 1.5%</td><td rowspan=1 colspan=1>28.6, 4.6%</td><td rowspan=1 colspan=1>682</td><td rowspan=1 colspan=1>3.7.0.5%</td><td rowspan=1 colspan=1>31.4,4.6%</td></tr><tr><td rowspan=1 colspan=1>SerumHigh</td><td rowspan=1 colspan=1>1176</td><td rowspan=1 colspan=1>17.4, 1.5%</td><td rowspan=1 colspan=1>56.1, 4.8%</td><td rowspan=1 colspan=1>1125</td><td rowspan=1 colspan=1>7.9, 0.7%</td><td rowspan=1 colspan=1>55.5, 4.9%</td><td rowspan=1 colspan=1>1255</td><td rowspan=1 colspan=1>7.2, 0.6%</td><td rowspan=1 colspan=1>58.4, 4.7%</td></tr><tr><td rowspan=1 colspan=1>PlasmaLow</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>2.8, 4.6%</td><td rowspan=1 colspan=1>3.1, 5.1%</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>1.8, 2.8%</td><td rowspan=1 colspan=1>2.8, 4.4%</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>1.8.2.8%</td><td rowspan=1 colspan=1>2.1,3.2%</td></tr><tr><td rowspan=1 colspan=1>PlasmaMid</td><td rowspan=1 colspan=1>619</td><td rowspan=1 colspan=1>11.1, 1.8%</td><td rowspan=1 colspan=1>25.8, 4.2%</td><td rowspan=1 colspan=1>605</td><td rowspan=1 colspan=1>8.8, 1.5%</td><td rowspan=1 colspan=1>32.4, 5.4%</td><td rowspan=1 colspan=1>666</td><td rowspan=1 colspan=1>13.0, 2.0%</td><td rowspan=1 colspan=1>36.5, 5.5%</td></tr><tr><td rowspan=1 colspan=1>PlasmaHigh</td><td rowspan=1 colspan=1>1140</td><td rowspan=1 colspan=1>16.1, 1.4%</td><td rowspan=1 colspan=1>57.1,5.0%</td><td rowspan=1 colspan=1>1111</td><td rowspan=1 colspan=1>14.4, 1.3%</td><td rowspan=1 colspan=1>51.1,4.6%</td><td rowspan=1 colspan=1>1221</td><td rowspan=1 colspan=1>11.7, 1.0%</td><td rowspan=1 colspan=1>54.7.4.5%</td></tr></table>

<table><tr><td>Performance</td></tr><tr><td>Data: In-House Matrix Comparison - Serum vs. Plasma</td></tr><tr><td></td></tr></table>

# Performance data for the Alfa Wassermann ACE Reagents run on the Alfa Wassermann ACE, ACE Alera and ACE Axcel Clinical Chemistry Systems

In-House Matrix Comparison: Serum vs. Plasma - ACE BUN/Urea Nitrogen   
Reagent   

<table><tr><td rowspan=1 colspan=1>System</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>Results - Serum vs. Plasma</td></tr><tr><td rowspan=1 colspan=1>ACE95 pairs</td><td rowspan=1 colspan=1>3-91 mg/dL</td><td rowspan=1 colspan=1>Slope: 0.979Intercept: 0.4Correlation: 0.9980Std. Error Est: 1.2Confidence Interval Slope: 0.966 to 0.992Confidence Interval Intercept: 0.0 to 0.7</td></tr><tr><td rowspan=1 colspan=1>ACE Alera96 pairs</td><td rowspan=1 colspan=1>3-96 mg/dL</td><td rowspan=1 colspan=1>Slope: 1.009Intercept: -0.1Correlation: 0.9976Std. Error Est: 1.4Confidence Interval Slope: 0.995 to 1.023Confidence Interval Intercept: -0.5 to 0.4</td></tr><tr><td rowspan=1 colspan=1>ACE Axce!51 pairs</td><td rowspan=1 colspan=1>3-100 mg/dL</td><td rowspan=1 colspan=1>Slope: 1.007Intercept: 0.3Correlation: 0.9944Std. Error Est: 2.4Confidence Interval Slope: 0.977 to 1.038Confidence Interval Intercept: -0.7 to 1.4</td></tr></table>

In-House Matrix Comparison: Serum vs. Plasma - ACE Creatinine Reagent   

<table><tr><td rowspan=1 colspan=1>System</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>Results - Serum vs. Plasma</td></tr><tr><td rowspan=1 colspan=1>ACE102 pairs</td><td rowspan=1 colspan=1>0.37-22.12 mg/dL</td><td rowspan=1 colspan=1> Slope: 1.014Intercept: -0.003Correlation: 0.9974Std. Error Est: 0.279Confidence Interval Slope: 1.000 to 1.029Confidence Interval Intercept: -0.068 to 0.062</td></tr><tr><td rowspan=1 colspan=1>ACE Alera102 pairs</td><td rowspan=1 colspan=1>0.41-23.15 mg/dL</td><td rowspan=1 colspan=1>Slope: 1.050Intercept: -0.077Correlation: 0.9984Std. Error Est: 0.197Confidence Interval Slope: 1.038 to 1.062Confidence Interval Intercept: -0.124 to -0.029</td></tr><tr><td rowspan=1 colspan=1>ACE Axcel55 pairs</td><td rowspan=1 colspan=1>0.37-23.45 mg/dL</td><td rowspan=1 colspan=1>Slope: 1.003Intercept: 0.005Correlation: 0.9993Std. Error Est: 0.197Confidence Interval Slope: 0.993 to 1.013Confidence Interval Intercept: -0.058 to 0.069</td></tr></table>

Performance

Data:

In-House   
Matrix   
ComparisonSerum vs.   
Plasma

In-House Matrix Comparison: Serum vs. Plasma - ACE Uric Acid Reagent   

<table><tr><td rowspan=1 colspan=1>System</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>Results - Serum vs. Plasma</td></tr><tr><td rowspan=1 colspan=1>ACE97 pairs</td><td rowspan=1 colspan=1>2.5-14.0 mg/dL</td><td rowspan=1 colspan=1>Slope: 1.008Intercept: -0.14Correlation: 0.9906Std. Error Est: 0.35Confidence Interval Slope: 0.980 to 1.036Confidence Interval Intercept: -0.34 to 0.06</td></tr><tr><td rowspan=1 colspan=1>ACE Alera95 pairs</td><td rowspan=1 colspan=1>2.5-14.4 mg/dL</td><td rowspan=1 colspan=1>Slope: 1.028Intercept: -0.29Correlation: 0.9836Std. Error Est: 0.48Confidence Interval Slope: 0.989 to 1.066Confidence Interval Intercept: -0.57 to -0.01</td></tr><tr><td rowspan=1 colspan=1>ACE Axcel55 pairs</td><td rowspan=1 colspan=1>1.8-15.6 mg/dL</td><td rowspan=1 colspan=1>Slope: 1.025Intercept: -0.09Correlation: 0.9879Std. Error Est: 0.42Confidence Interval Slope: 0.981 to 1.069Confidence Interval Intercept: -0.39 to 0.21</td></tr></table>

In-House Matrix Comparison: Serum vs. Plasma - ACE CK Reagent   

<table><tr><td rowspan=1 colspan=1>System</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>Results - Serum vs. Plasma</td></tr><tr><td rowspan=1 colspan=1>ACE94 pairs</td><td rowspan=1 colspan=1>: 11-1234 U/L</td><td rowspan=1 colspan=1>Slope: 0.997Intercept: -0.5Correlation: 0.9965Std. Error Est: 23.5Confidence Interval Slope: 0.980 to 1.014Confidence Interval Intercept: -6.3 to 5.2</td></tr><tr><td rowspan=1 colspan=1>ACE Alera96 pairs</td><td rowspan=1 colspan=1>14-1211 U/L</td><td rowspan=1 colspan=1>Slope: 0.978Intercept: 0.1Correlation: 0.9960Std. Error Est: 22.1Confidence Interval Slope: 0.960 to 0.996Confidence Interval Intercept: -5.2 to 5.5</td></tr><tr><td rowspan=1 colspan=1>ACE Axcel55 pairs</td><td rowspan=1 colspan=1>17-1315 U/L</td><td rowspan=1 colspan=1>Slope: 1.006Intercept: -0.50Correlation: 0.9990Std. Error Est: 13.24Confidence Interval Slope: 0.993 to 1.019Confidence Interval Intercept: -4.74 to 3.74</td></tr></table>

Performance

Data:

Precision - POL

# POL - Precision for ACE and ACE Alera Clinical Chemistry Systems

(Note: Refer to previously cleared submission k113389 for ACE Axcel POL data)

<table><tr><td rowspan=2 colspan=3>BUN/Urea</td><td rowspan=1 colspan=2>ACE Result</td><td rowspan=3 colspan=1>Mean</td><td rowspan=1 colspan=2>ACE Alera Result</td></tr><tr><td rowspan=1 colspan=2>mg/dL SD, %CV</td><td rowspan=1 colspan=2>mg/dL SD, %CV</td></tr><tr><td rowspan=1 colspan=1>Lab</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>8</td><td rowspan=1 colspan=1>0.00 SD</td><td rowspan=1 colspan=1>0.30 SD</td><td rowspan=2 colspan=1>8</td><td rowspan=1 colspan=1>0.40 SD</td><td rowspan=1 colspan=1>0.60 SD</td></tr><tr><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>4.0%</td><td rowspan=1 colspan=1>5.5%</td><td rowspan=1 colspan=1>7.7%</td></tr><tr><td rowspan=2 colspan=1>POL</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>8</td><td rowspan=1 colspan=1>0.30 SD</td><td rowspan=1 colspan=1>0.30 SD</td><td rowspan=2 colspan=1>9</td><td rowspan=1 colspan=1>0.40 SD</td><td rowspan=1 colspan=1>0.50 SD</td></tr><tr><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=1>4.5%</td><td rowspan=1 colspan=1>6.2%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>I</td><td rowspan=2 colspan=1>8</td><td rowspan=1 colspan=1>0.40 SD</td><td rowspan=1 colspan=1>0.50 SD</td><td rowspan=2 colspan=1>8</td><td rowspan=1 colspan=1>0.20 SD</td><td rowspan=1 colspan=1>0.40 SD</td></tr><tr><td rowspan=1 colspan=1>4.4%</td><td rowspan=1 colspan=1>5.6%</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>4.9%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>8</td><td rowspan=1 colspan=1>0.30 SD</td><td rowspan=1 colspan=1>0.30 SD</td><td rowspan=2 colspan=1>9.</td><td rowspan=1 colspan=1>0.30 SD</td><td rowspan=1 colspan=1>0.70 SD</td></tr><tr><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=1>3.6%</td><td rowspan=1 colspan=1>. 8.3%</td></tr><tr><td rowspan=1 colspan=8>:</td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>41</td><td rowspan=1 colspan=1>1.90 SD</td><td rowspan=1 colspan=1>2.00 SD</td><td rowspan=2 colspan=1>42</td><td rowspan=1 colspan=1>1.30 SD</td><td rowspan=1 colspan=1>1.60 SD</td></tr><tr><td rowspan=1 colspan=1>4.7%</td><td rowspan=1 colspan=1>5.0%</td><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>3.9%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>43</td><td rowspan=1 colspan=1>0.40 SD</td><td rowspan=1 colspan=1>0.80 SD</td><td rowspan=2 colspan=1>43</td><td rowspan=1 colspan=1>1.40 SD</td><td rowspan=1 colspan=1>1.70 SD</td></tr><tr><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>4.0%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>42</td><td rowspan=1 colspan=1>0.30 SD</td><td rowspan=1 colspan=1>1.40 SD</td><td rowspan=2 colspan=1>41</td><td rowspan=1 colspan=1>1.10 SD</td><td rowspan=1 colspan=1>1.80 SD</td></tr><tr><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>4.4%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>42 •</td><td rowspan=1 colspan=1>1.00 SD</td><td rowspan=1 colspan=1>1.10 SD</td><td rowspan=2 colspan=1>44</td><td rowspan=1 colspan=1>0.70 SD</td><td rowspan=1 colspan=1>1.40 SD</td></tr><tr><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>2.6%</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>3.3%</td></tr><tr><td rowspan=1 colspan=8></td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>74</td><td rowspan=1 colspan=1>1.10 SD</td><td rowspan=1 colspan=1>2.40 SD</td><td rowspan=2 colspan=1>75</td><td rowspan=1 colspan=1>0.40 SD</td><td rowspan=1 colspan=1>2.00 SD</td></tr><tr><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>0.5%</td><td rowspan=1 colspan=1>2.6%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>75</td><td rowspan=1 colspan=1>1.30 SD</td><td rowspan=1 colspan=1>1.30 SD</td><td rowspan=2 colspan=1>76</td><td rowspan=1 colspan=1>1.20 SD</td><td rowspan=1 colspan=1>1.80 SD</td></tr><tr><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>2.4%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>73</td><td rowspan=1 colspan=1>1.30 SD</td><td rowspan=1 colspan=1>2.30 SD</td><td rowspan=2 colspan=1>74</td><td rowspan=1 colspan=1>1.70 SD</td><td rowspan=1 colspan=1>2.80 SD</td></tr><tr><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>3.1%</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>3.7%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>76</td><td rowspan=1 colspan=1>1.20 SD</td><td rowspan=1 colspan=1>1.40 SD</td><td rowspan=2 colspan=1>76</td><td rowspan=1 colspan=1>1.10 SD</td><td rowspan=1 colspan=1>2.20 SD</td></tr><tr><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>2.9%</td></tr></table>

Data at POL:

<table><tr><td>Data at POL: Precision- POL</td><td></td></tr></table>

<table><tr><td rowspan=2 colspan=3>Creatinine</td><td rowspan=1 colspan=2>ACE Result</td><td rowspan=3 colspan=1>Mean</td><td rowspan=1 colspan=2>ACE Alera Result</td></tr><tr><td rowspan=1 colspan=2>mg/dL SD, %CV</td><td rowspan=1 colspan=2>mg/dL SD, %CV</td></tr><tr><td rowspan=1 colspan=1>Lab</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>0.58</td><td rowspan=1 colspan=1>0.04 SD</td><td rowspan=1 colspan=1>0.05 SD</td><td rowspan=2 colspan=1>0.58</td><td rowspan=1 colspan=1>0.02 SD</td><td rowspan=1 colspan=1>0.03 SD</td></tr><tr><td rowspan=1 colspan=1>6.4%</td><td rowspan=1 colspan=1>8.8%</td><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>5.3%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>0.51</td><td rowspan=1 colspan=1>0.03 SD</td><td rowspan=1 colspan=1>0.04 SD</td><td rowspan=2 colspan=1>0.53</td><td rowspan=1 colspan=1>0.03 SD</td><td rowspan=1 colspan=1>0.05 SD</td></tr><tr><td rowspan=1 colspan=1>5.6%</td><td rowspan=1 colspan=1>8.4%</td><td rowspan=1 colspan=1>6.0%</td><td rowspan=1 colspan=1>9.3%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>0.54</td><td rowspan=1 colspan=1>0.04 SD</td><td rowspan=1 colspan=1>0.05 SD</td><td rowspan=2 colspan=1>0.56</td><td rowspan=1 colspan=1>0.02 SD</td><td rowspan=1 colspan=1>0.03 SD</td></tr><tr><td rowspan=1 colspan=1>6.9%</td><td rowspan=1 colspan=1>9.8%</td><td rowspan=1 colspan=1>4.2%</td><td rowspan=1 colspan=1>4.4%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>0.53</td><td rowspan=1 colspan=1>0.04 SD</td><td rowspan=1 colspan=1>0.04 SD</td><td rowspan=2 colspan=1>0.55</td><td rowspan=1 colspan=1>0.02 SD</td><td rowspan=1 colspan=1>0.04 SD</td></tr><tr><td rowspan=1 colspan=1>6.6%</td><td rowspan=1 colspan=1>7.5%</td><td rowspan=1 colspan=1>4.3%</td><td rowspan=1 colspan=1>6.3%</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>8.29</td><td rowspan=1 colspan=1>0.09 SD</td><td rowspan=1 colspan=1>0.32 SD</td><td rowspan=2 colspan=1>8.08</td><td rowspan=1 colspan=1>0.11 SD</td><td rowspan=1 colspan=1>0.28 SD</td></tr><tr><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>3.5%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>7.97</td><td rowspan=1 colspan=1>0.08 SD</td><td rowspan=1 colspan=1>0.20 SD</td><td rowspan=2 colspan=1>7.84</td><td rowspan=1 colspan=1>0.08 SD</td><td rowspan=1 colspan=1>0.15 SD</td></tr><tr><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>1.9%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>7.60</td><td rowspan=1 colspan=1>0.11 SD</td><td rowspan=1 colspan=1>0.43 SD</td><td rowspan=2 colspan=1>8.21</td><td rowspan=1 colspan=1>0.14 SD</td><td rowspan=1 colspan=1>0.23 SD</td></tr><tr><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>5.7%</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>2.8%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>7.89</td><td rowspan=1 colspan=1>0.11 SD</td><td rowspan=1 colspan=1>0.13 SD</td><td rowspan=2 colspan=1>7.98</td><td rowspan=1 colspan=1>0.09 SD</td><td rowspan=1 colspan=1>0.23 SD</td></tr><tr><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>2.9%</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>12.92</td><td rowspan=1 colspan=1>0.18 SD</td><td rowspan=1 colspan=1>0.46 SD</td><td rowspan=2 colspan=1>12.65</td><td rowspan=1 colspan=1>0.07 SD</td><td rowspan=1 colspan=1>0.42 SD</td></tr><tr><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>0.5%</td><td rowspan=1 colspan=1>3.3%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>3.</td><td rowspan=2 colspan=1>12.42</td><td rowspan=1 colspan=1>0.23 SD</td><td rowspan=1 colspan=1>0.37SD</td><td rowspan=2 colspan=1>12.32</td><td rowspan=1 colspan=1>0.10 SD</td><td rowspan=1 colspan=1>0.42 SD</td></tr><tr><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>3.4%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>11.67</td><td rowspan=1 colspan=1>0.22 SD</td><td rowspan=1 colspan=1>0.53 SD</td><td rowspan=2 colspan=1>12.81</td><td rowspan=1 colspan=1>0.31 SD</td><td rowspan=1 colspan=1>0.50 SD</td></tr><tr><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>4.5%</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>3.9%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>12.28</td><td rowspan=1 colspan=1>0.17 SD</td><td rowspan=1 colspan=1>0.18 SD</td><td rowspan=2 colspan=1>12.27</td><td rowspan=1 colspan=1>0.12 SD</td><td rowspan=1 colspan=1>0.44 SD</td></tr><tr><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>3.6%</td></tr></table>

Performance Data at POL:

Precision - POL

<table><tr><td rowspan=2 colspan=3>Uric Acid</td><td rowspan=1 colspan=2>ACE Result</td><td rowspan=3 colspan=1>Mean</td><td rowspan=1 colspan=2>ACE Alera Result</td></tr><tr><td rowspan=1 colspan=2>mg/dL SD, %CV</td><td rowspan=1 colspan=2>mg/dL SD, %CV</td></tr><tr><td rowspan=1 colspan=1>Lab</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>2.9</td><td rowspan=1 colspan=1>0.19 SD</td><td rowspan=1 colspan=1>0.19 SD</td><td rowspan=2 colspan=1>2.9</td><td rowspan=1 colspan=1>0.10 SD</td><td rowspan=1 colspan=1>0.13 SD</td></tr><tr><td rowspan=1 colspan=1>6.5%</td><td rowspan=1 colspan=1>6.5%</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>4.5%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>3.0</td><td rowspan=1 colspan=1>0.05 SD</td><td rowspan=1 colspan=1>0.09 SD</td><td rowspan=2 colspan=1>3.0.</td><td rowspan=1 colspan=1>0.15 SD</td><td rowspan=1 colspan=1>0.16 SD</td></tr><tr><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>3.1%</td><td rowspan=1 colspan=1>5.2%</td><td rowspan=1 colspan=1>5.3%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>2.8</td><td rowspan=1 colspan=1>0.10 SD</td><td rowspan=1 colspan=1>0.11 SD</td><td rowspan=2 colspan=1>2.9</td><td rowspan=1 colspan=1>0.09 SD</td><td rowspan=1 colspan=1>0.10 SD</td></tr><tr><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>4.0%</td><td rowspan=1 colspan=1>3.1%</td><td rowspan=1 colspan=1>3.6%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>2.9</td><td rowspan=1 colspan=1>0.06 SD</td><td rowspan=1 colspan=1>0.14 SD</td><td rowspan=2 colspan=1>3.2</td><td rowspan=1 colspan=1>0.05 SD</td><td rowspan=1 colspan=1>0.09 SD</td></tr><tr><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>5.0%</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>2.9%</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>8.0</td><td rowspan=1 colspan=1>0.13 SD</td><td rowspan=1 colspan=1>0.15 SD</td><td rowspan=2 colspan=1>8.0</td><td rowspan=1 colspan=1>0.05 SD</td><td rowspan=1 colspan=1>0.17 SD</td></tr><tr><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>2.1%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>7.7</td><td rowspan=1 colspan=1>0.05 SD</td><td rowspan=1 colspan=1>0.11 SD</td><td rowspan=2 colspan=1>7.6</td><td rowspan=1 colspan=1>0.13 SD</td><td rowspan=1 colspan=1>0.21 SD</td></tr><tr><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>2.8%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>7.5</td><td rowspan=1 colspan=1>0.13 SD</td><td rowspan=1 colspan=1>0.16 SD</td><td rowspan=2 colspan=1>7.5</td><td rowspan=1 colspan=1>0.08 SD</td><td rowspan=1 colspan=1>0.13 SD</td></tr><tr><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>1.8%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>7.9</td><td rowspan=1 colspan=1>0.10 SD</td><td rowspan=1 colspan=1>0.13 SD</td><td rowspan=2 colspan=1>7.9</td><td rowspan=1 colspan=1>0.07 SD</td><td rowspan=1 colspan=1>0.25 SD</td></tr><tr><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>3.1%</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>•  3</td><td rowspan=2 colspan=1>12.5</td><td rowspan=1 colspan=1>0.35 SD</td><td rowspan=1 colspan=1>0.38 SD</td><td rowspan=2 colspan=1>12.7</td><td rowspan=1 colspan=1>0.18 SD</td><td rowspan=1 colspan=1>0.22 SD</td></tr><tr><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>1.7%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>12.0</td><td rowspan=1 colspan=1>0.13 SD</td><td rowspan=1 colspan=1>0.28 SD</td><td rowspan=2 colspan=1>11.9</td><td rowspan=1 colspan=1>0.14 SD</td><td rowspan=1 colspan=1>0.26 SD</td></tr><tr><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>2.2%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>:3</td><td rowspan=2 colspan=1>11.8</td><td rowspan=1 colspan=1>0.29 SD</td><td rowspan=1 colspan=1>0.32 SD</td><td rowspan=2 colspan=1>11.6</td><td rowspan=1 colspan=1>0.27 SD</td><td rowspan=1 colspan=1>0.27 SD</td></tr><tr><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>2.4%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>12.3</td><td rowspan=1 colspan=1>0.11 SD</td><td rowspan=1 colspan=1>0.12 SD</td><td rowspan=2 colspan=1>12.2</td><td rowspan=1 colspan=1>0.15 SD</td><td rowspan=1 colspan=1>0.35 SD</td></tr><tr><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>2.9%</td></tr></table>

<table><tr><td>Data at POL: Precision - POL</td></tr><tr><td></td></tr><tr><td></td></tr></table>

<table><tr><td rowspan=2 colspan=3>CK</td><td rowspan=1 colspan=2>ACE Result</td><td rowspan=3 colspan=1>Mean</td><td rowspan=1 colspan=2>ACE Alera Result</td></tr><tr><td rowspan=1 colspan=2>mg/dL SD, %CV</td><td rowspan=1 colspan=2>mg/dLSD, %CV</td></tr><tr><td rowspan=1 colspan=1>Lab</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>77</td><td rowspan=1 colspan=1>3.20 SD</td><td rowspan=1 colspan=1>4.00 SD</td><td rowspan=2 colspan=1>75</td><td rowspan=1 colspan=1>2.50 SD</td><td rowspan=1 colspan=1>3.30 SD</td></tr><tr><td rowspan=1 colspan=1>4.2%</td><td rowspan=1 colspan=1>5.2%</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>4.4%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>70</td><td rowspan=1 colspan=1>1.40 SD</td><td rowspan=1 colspan=1>2.90 SD</td><td rowspan=2 colspan=1>73</td><td rowspan=1 colspan=1>1.40 SD</td><td rowspan=1 colspan=1>2.60 SD</td></tr><tr><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>4.1%</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>3.6%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>69</td><td rowspan=1 colspan=1>1.90 SD</td><td rowspan=1 colspan=1>3.00 SD</td><td rowspan=2 colspan=1>70</td><td rowspan=1 colspan=1>2.20 SD</td><td rowspan=1 colspan=1>3.50 SD</td></tr><tr><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>4.4%</td><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>5.0%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>79</td><td rowspan=1 colspan=1>2.60 SD</td><td rowspan=1 colspan=1>2.70 SD</td><td rowspan=2 colspan=1>70</td><td rowspan=1 colspan=1>2.10 SD</td><td rowspan=1 colspan=1>4.10 SD</td></tr><tr><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>5.9%</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>521</td><td rowspan=1 colspan=1>6.70 SD</td><td rowspan=1 colspan=1>7.20 SD</td><td rowspan=2 colspan=1>516</td><td rowspan=1 colspan=1>8.00 SD</td><td rowspan=1 colspan=1>8.10 SD</td></tr><tr><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>1.6%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>568</td><td rowspan=1 colspan=1>4.90 SD</td><td rowspan=1 colspan=1>6.90 SD</td><td rowspan=2 colspan=1>567</td><td rowspan=1 colspan=1>10.00 SD</td><td rowspan=1 colspan=1>14.00 SD</td></tr><tr><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>2.5%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>526</td><td rowspan=1 colspan=1>3.90 SD</td><td rowspan=1 colspan=1>9.20 SD</td><td rowspan=2 colspan=1>514</td><td rowspan=1 colspan=1>6.50 SD</td><td rowspan=1 colspan=1>8.80 SD</td></tr><tr><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>1.7%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>540</td><td rowspan=1 colspan=1>4.00 SD</td><td rowspan=1 colspan=1>4.30 SD</td><td rowspan=2 colspan=1>559</td><td rowspan=1 colspan=1>6.90 SD</td><td rowspan=1 colspan=1>14.10 SD</td></tr><tr><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>2.5%</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>907</td><td rowspan=1 colspan=1>10.90SD</td><td rowspan=1 colspan=1>14.60SD</td><td rowspan=2 colspan=1>905</td><td rowspan=1 colspan=1>9.50 SD</td><td rowspan=1 colspan=1>14.00 SD</td></tr><tr><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>1.6%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>967</td><td rowspan=1 colspan=1>22.00SD</td><td rowspan=1 colspan=1>22.70SD</td><td rowspan=2 colspan=1>995</td><td rowspan=1 colspan=1>7.60 SD</td><td rowspan=1 colspan=1>14.40 SD</td></tr><tr><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>1.4%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>929</td><td rowspan=1 colspan=1>18.60SD</td><td rowspan=1 colspan=1>18.90SD</td><td rowspan=2 colspan=1>899</td><td rowspan=1 colspan=1>11.40SD</td><td rowspan=1 colspan=1>11.60SD</td></tr><tr><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>1.3%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>950</td><td rowspan=1 colspan=1>7.80 SD</td><td rowspan=1 colspan=1>9.90 SD</td><td rowspan=2 colspan=1>977</td><td rowspan=1 colspan=1>13.00SD</td><td rowspan=1 colspan=1>19.60 SD</td></tr><tr><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>2.0%</td></tr></table>

Performance

Data:

Method Comparison - POL on ACE   

<table><tr><td rowspan=1 colspan=1>ageni</td><td rowspan=1 colspan=1>Statistic</td><td rowspan=1 colspan=1>In-House ACE (x)vS.POL 1 ACE (y)</td><td rowspan=1 colspan=1>In-House ACE (x)vS.POL 2 ACE (y)</td><td rowspan=1 colspan=1>In-House ACE (x)vS.POL 3 ACE (y)</td></tr><tr><td rowspan=1 colspan=1>BUN</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.CI SlopeCI Intercept</td><td rowspan=1 colspan=1>533 to 88y = 1.034x - 0.10.99890.91.020 to 1.047-0.5 to 0.2</td><td rowspan=1 colspan=1>54 .3 to 88y = 1.025x ± 0.00.99851.11.010 to 1.040-0.4 to 0.5</td><td rowspan=1 colspan=1>543 to 88y = 1.03 1 x + 0.00.99900.91.018 to 1.044-0.3 to 0.4</td></tr><tr><td rowspan=1 colspan=1>Creatinine</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.CI SlopeCI Intercept</td><td rowspan=1 colspan=1>510.34 to 22.57y= 1.032x -0.0100.99940.1481.022 to 1.042-0.057 to 0.037</td><td rowspan=1 colspan=1>510.34 to 22.57y = 1.010x - 0.0460.99970.1001.003 to 1.016-0.078 to -0.014</td><td rowspan=1 colspan=1>510.34 to 22.57y = 0.986x - 0.0170.99990.0600.982 to 0.990-0.036 to 0.002</td></tr><tr><td rowspan=1 colspan=1>Uric Acid</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.CI SlopeCI Intercept</td><td rowspan=1 colspan=1>491.7 to 14.5y = 0.988x + 0.230.99390.270.956 to 1.0200.01 to 0.45</td><td rowspan=1 colspan=1>491.7 to 14.5y = 1.018x - 0.060.99570.230.991 to 1.046-0.25 to 0.13</td><td rowspan=1 colspan=1>49.1.7 to 14.5. y= 1.009x + 0.030.99690.190.985 to 1.032-0.13 to 0.19</td></tr><tr><td rowspan=1 colspan=1>Creatininekinase</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.Cl SlopeCI Intercept</td><td rowspan=1 colspan=1>5011 to 1204y = 1.010x - 7.70.997619.20.990 to 1.031-14.7 to -0.7</td><td rowspan=1 colspan=1>4811 to 1204y= 0.989x - 8.00.998713.90.974 to 1.004-13.2 to -2.8</td><td rowspan=1 colspan=1>491 1 to 1204y = 0.986x - 1.80.99967.70.978 to 0.995-4.6 to 1.1</td></tr></table>

Performance Data at POL:

Method   
Comparison - POL on ACE Alera

# POL  Method Comparison for ACE Alera Clinical Chemistry System

<table><tr><td rowspan=1 colspan=1>Reagent</td><td rowspan=1 colspan=1>Statistic</td><td rowspan=1 colspan=1>In-House ACE (x)vS.POL 1 Alera (y)</td><td rowspan=1 colspan=1>In-House ACE (x)VS.POL 2 Alera (y)</td><td rowspan=1 colspan=1>In-House ACE (x)VS.POL 3 Alera (y)</td></tr><tr><td rowspan=1 colspan=1>BUN</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.CI SlopeCI Intercept</td><td rowspan=1 colspan=1>533 to 88y = 1.039x + 0.30.99870.91.024 to 1.053-0.1 to 0.6</td><td rowspan=1 colspan=1>533 to 88y = 1.01 1 x + 0.20.99900.80.998 to 1.023-0.1 to 0.6</td><td rowspan=1 colspan=1>533 to 88y=1.019x+1.00.99721.40.997 to 1.0400.4 to 1.6</td></tr><tr><td rowspan=1 colspan=1>Creatinine</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.CI SlopeCI Intercept</td><td rowspan=1 colspan=1>510.34 to 22.57y = 0.987x - 0.0120.99930.1490.977 to 0.998-0.059 to 0.036</td><td rowspan=1 colspan=1>51 .0.34 to 22.57y = 1.041x -0.0380.99940.1491.031 to 1.051-0.085 to 0.010</td><td rowspan=1 colspan=1>510.34 to 22.57y= 1.000x - 0.0130.99860.2200.985 to 1.015-0.083 to 0.057</td></tr><tr><td rowspan=1 colspan=1>Uric acid</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.CI SlopeCI Intercept</td><td rowspan=1 colspan=1>491.7 to 14.5y = 0.967x + 0.370.99410.260.936 to 0.9980.16 to 0.58</td><td rowspan=1 colspan=1>491.7 to 14.5y = 0.964x + 0.210.99510.23 0.936 to 0.9920.02 to 0.40</td><td rowspan=1 colspan=1>491.7 to 14.0y = 0.994x + 0.290.99090.330.955 to 1.0340.02 to 0.56</td></tr><tr><td rowspan=1 colspan=1>CreatinineKinase</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.CI SlopeCI Intercept</td><td rowspan=1 colspan=1>501 1 to 1204y = 1.043x - 6.40.99949.81.032 to 1.053-9.9 to -2.8</td><td rowspan=1 colspan=1>4911 to 1204 y= 0.971x -2.30.99957.50.962 to 0.980-5.1 to 0.5</td><td rowspan=1 colspan=1>501 1 to 1204y= 0.983x - 8.70.996821.50.960 to 1.006-16.5 to -0.9</td></tr></table>

Performance Data:

ACE Alera

<table><tr><td>Performance data for the Alfa Wassermann ACE Reagents run on the</td></tr><tr><td>Alfa Wassermann ACE Alera Clinical Chemistry Systems</td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr><tr><td>Detection Limits - ACE Alera Clinical Chemistry System</td></tr><tr><td></td></tr></table>

<table><tr><td rowspan=1 colspan=1>ACE Alera</td><td rowspan=1 colspan=1>BUN(mg/dL)</td><td rowspan=1 colspan=1>Creatinine(mg/dL)</td><td rowspan=1 colspan=1>Uric Acid(mg/dL)</td><td rowspan=1 colspan=1>CK(U/L)</td></tr><tr><td rowspan=1 colspan=1>LoB</td><td rowspan=1 colspan=1>1.53</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>1.11</td><td rowspan=1 colspan=1>4.68</td></tr><tr><td rowspan=1 colspan=1>LoD</td><td rowspan=1 colspan=1>1.97</td><td rowspan=1 colspan=1>0.18</td><td rowspan=1 colspan=1>1.34</td><td rowspan=1 colspan=1>8.30</td></tr><tr><td rowspan=1 colspan=1>LoQ (claimed)</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>0.33</td><td rowspan=1 colspan=1>1.50</td><td rowspan=1 colspan=1>11.0</td></tr></table>

# Linearity - ACE Alera Clinical Chemistry System

<table><tr><td rowspan=1 colspan=1>ACEReagents</td><td rowspan=1 colspan=1>Lowleveltested</td><td rowspan=1 colspan=1>Upper leveltested</td><td rowspan=1 colspan=1>Linear to:</td><td rowspan=1 colspan=1>Linear RegressionEquation</td><td rowspan=1 colspan=1>CorrelationCoefficientsR^2</td></tr><tr><td rowspan=1 colspan=1>BUN(mg/dL)</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>108.7</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>y=1.011x + 0.1</td><td rowspan=1 colspan=1>0.9991</td></tr><tr><td rowspan=1 colspan=1>Creatinine(mg/dL)</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>32.4</td><td rowspan=1 colspan=1>25.0</td><td rowspan=1 colspan=1>y=1.002x + 0.06</td><td rowspan=1 colspan=1>0.9981</td></tr><tr><td rowspan=1 colspan=1>Uric Acid(mg/dL)</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>17.3</td><td rowspan=1 colspan=1>16.0</td><td rowspan=1 colspan=1>y=0.994x - 0.10</td><td rowspan=1 colspan=1>0.9939</td></tr><tr><td rowspan=1 colspan=1>CK(U/L)</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>1416.7</td><td rowspan=1 colspan=1>1350.0</td><td rowspan=1 colspan=1>y=1.053x - 2.6</td><td rowspan=1 colspan=1>0.9975</td></tr></table>

Performance Data:

ACE Alera

<table><tr><td rowspan=1 colspan=1>ACEAlera</td><td rowspan=1 colspan=1>Icterus</td><td rowspan=1 colspan=1>Hemolysis</td><td rowspan=1 colspan=1>Lipemia(Intralipid)/Triglycerides</td><td rowspan=1 colspan=1>Ascorbic Acid</td></tr><tr><td rowspan=1 colspan=1>BUN</td><td rowspan=1 colspan=1>No significantinterference at orbelow 70 mg/dL</td><td rowspan=1 colspan=1>No significantinterference at orbelow 500 mg/dL</td><td rowspan=1 colspan=1>No significantinterference at orbelow 2080 mg/dLTriglycerides</td><td rowspan=1 colspan=1>No significantinterference at orbelow 6 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Creatinine</td><td rowspan=1 colspan=1>No significantinterference at orbelow 6.0 mg/dL</td><td rowspan=1 colspan=1>No significantinterference at orbelow 1000 mg/dL</td><td rowspan=1 colspan=1>No significantinterference at orbelow 2080 mg/dLTriglycerides</td><td rowspan=1 colspan=1>. No significantinterference at orbelow 6 mg/dL</td></tr><tr><td rowspan=1 colspan=1>UA</td><td rowspan=1 colspan=1>No significantinterference at orbelow 16.9 mg/dL</td><td rowspan=1 colspan=1>No significantinterference at orbelow 125 mg/dL</td><td rowspan=1 colspan=1>No significantinterference at orbelow 893 mg/dLTriglycerides</td><td rowspan=1 colspan=1>No significantinterference at orbelow 1.313mg/dL</td></tr><tr><td rowspan=1 colspan=1> CK</td><td rowspan=1 colspan=1>No significantinterference at orbelow 30 mg/dL</td><td rowspan=1 colspan=1>No significantinterference at orbelow 125 mg/dL</td><td rowspan=1 colspan=1>No significantinterference at orbelow 2372 mg/dLTriglycerides</td><td rowspan=1 colspan=1>No significantinterference at orbelow 6 mg/dL</td></tr></table>

Performance Data: ACE Alera

<table><tr><td rowspan=2 colspan=2>on ACE Alera</td><td rowspan=1 colspan=3>Precision (SD, %CV)</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>BUNmg/dL</td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0.3, 2.1%</td><td rowspan=1 colspan=1>0.5, 3.1%</td></tr><tr><td rowspan=1 colspan=1>Mid</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>0.7, 1.7%</td><td rowspan=1 colspan=1>1.3, 3.0%</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>74</td><td rowspan=1 colspan=1>1.5, 2.0%</td><td rowspan=1 colspan=1>2.3, 3.2%</td></tr><tr><td rowspan=3 colspan=1>Creatininemg/dL</td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.03, 3.9%</td><td rowspan=1 colspan=1>0.08, 9.8%</td></tr><tr><td rowspan=1 colspan=1>Mid</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>0.04, 2.4%</td><td rowspan=1 colspan=1>0.12, 7.5%</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>0.13, 2.5%</td><td rowspan=1 colspan=1>0.22, 4.1%</td></tr><tr><td rowspan=3 colspan=1>Uric Acidmg/dL</td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>0.10, 3.0%</td><td rowspan=1 colspan=1>0.18, 5.2%</td></tr><tr><td rowspan=1 colspan=1>Mid</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>0.14, 2.3%</td><td rowspan=1 colspan=1>0.25, 4.1%</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>11.6</td><td rowspan=1 colspan=1>0.32, 2.8%</td><td rowspan=1 colspan=1>0.55, 4.7%</td></tr><tr><td rowspan=3 colspan=1>CKU/L</td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>128</td><td rowspan=1 colspan=1>2.2, 1.7%</td><td rowspan=1 colspan=1>3.8, 3.0%</td></tr><tr><td rowspan=1 colspan=1>Mid</td><td rowspan=1 colspan=1>378</td><td rowspan=1 colspan=1>6.8, 1.8%</td><td rowspan=1 colspan=1> 11.5, 3.0%</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>865</td><td rowspan=1 colspan=1>8.5, 1.0%</td><td rowspan=1 colspan=1>16.2, 1.9%</td></tr></table>

In-House ACE (x) vs. In-House ACE Alera (y)   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>BUN(mg/dL)</td><td rowspan=1 colspan=1>Creatinine(mg/dL)</td><td rowspan=1 colspan=1>Uric Acid(mg/dL)</td><td rowspan=1 colspan=1>CK(U/L)</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>49</td></tr><tr><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>3 - 88</td><td rowspan=1 colspan=1>0.34  22.57</td><td rowspan=1 colspan=1>1.7- 14.5</td><td rowspan=1 colspan=1>11 - 1204</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>1.000</td><td rowspan=1 colspan=1>1.016</td><td rowspan=1 colspan=1>0.992</td><td rowspan=1 colspan=1>0.991</td></tr><tr><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>-0.002</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>-1.3</td></tr><tr><td rowspan=1 colspan=1>CorrelationCoefficient</td><td rowspan=1 colspan=1>0.9988</td><td rowspan=1 colspan=1>0.9997</td><td rowspan=1 colspan=1>0.9978</td><td rowspan=1 colspan=1>0.9999</td></tr><tr><td rowspan=1 colspan=1>Std. Error</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.111</td><td rowspan=1 colspan=1>0:17</td><td rowspan=1 colspan=1>-1.3</td></tr><tr><td rowspan=1 colspan=1>CI Slope</td><td rowspan=1 colspan=1>0.986 to 1.014</td><td rowspan=1 colspan=1>1.008 to 1.023</td><td rowspan=1 colspan=1>0.973 to 1.010</td><td rowspan=1 colspan=1>0.987 to 0.995</td></tr><tr><td rowspan=1 colspan=1>CI Intercept</td><td rowspan=1 colspan=1>-0.3 to 0.4</td><td rowspan=1 colspan=1>-0.038 to 0.0.34</td><td rowspan=1 colspan=1>-0.09 to 0.18</td><td rowspan=1 colspan=1>-2.6 to 0.0</td></tr></table>

<table><tr><td>Conclusions:</td><td>Based on the foregoing data, the device is safe and effective for use in clinical laboratories and physician office laboratories. These data indicate substantial equivalence for lithium heparin plasma sample collection tubes to the predicate device&#x27;s use of serum</td></tr></table>

<table><tr><td>Performance Data: ACE Alera Conclusions:</td></tr><tr><td></td><td></td></tr></table>

Alfa Wassermann Diagnostic Technologies, LLC C/O Hyman Katz, Ph.D.   
4 Henderson Drive   
WEST CALDWELL NJ 07006

Re: K123322 Trade/Device Name: ACE BUN/Urea Reagent, ACE Creatinine Reagent, ACE Uric Acid Reagent, ACE CK Reagent Regulation Number: 21 CFR 862.1770 Regulation Name: Urea nitrogen test system Regulatory Class: II Product Code: CDN, CGX, KNK, CGS Dated: March 07, 2013 Received: March 20, 2013

Dear Dr. Katz:

We have reviewed your Section $5 1 0 ( \mathbf { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050.

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Small Manufacturers, International and Consumer   
Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

# Carol C. Benson -S for

Courtney H. Lias, Ph.D.   
Director, Division of Chemistry and Toxicology Devices   
Office of In Vitro Diagnostics and Radiological Health   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number (if known): k123322

Device Name: ACE BUN/Urea Reagent

Indications for Use: The ACE BUN/Urea Reagent is intended for the quantitative determination of blood urea nitrogen (BUN) concentration in serum and lithium heparin plasma using the ACE, ACE Alera, and ACE Axcel Clinical Chemistry Systems. BUN measurements are used in the diagnosis and treatment of certain renal and metabolic diseases. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.

Device Name: ACE Creatinine Reagent

Indications for Use: The ACE Creatinine Reagent is intended for the quantitative determination of creatinine concentration in serum and lithium heparin plasma using the ACE, ACE Alera, and ACE Axcel Clinical Chemistry Systems. Creatinine measurements are used in the diagnosis and treatment of renal diseases, in monitoring renal dialysis, and as a calculation basis for measuring other urine analytes. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only

Concuence of CDRH, Offe of In Vito Dagnostic nd Radiological Health (OIR)

# Indications for Use

# 510(k) Number (if known): k123322

Device Name: ACE Uric Acid Reagent

Indications for Use: The ACE Uric Acid Reagent is intended for the quantitative determination of uric acid concentration in serum and lithium heparin plasma using the ACE, ACE Alera, and ACE Axcel Clinical Chemistry Systems. Uric acid measurements are used in the diagnosis and treatment of numerous renal and metabolic disorders, including renal failure, gout, leukemia, psoriasis, starvation or other wasting conditions and of patients receiving cytotoxic drugs. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.

Device Name: ACE CK Reagent

Indications for Use: The ACE CK Reagent is intended for the quantitative determination of creatine kinase activity in serum and lithium heparin plasma using the ACE, ACE Alera, and ACE Axcel Clinical Chemistry Systems. Measurement of creatine kinase is used in the diagnosis and treatment of myocardial infarction and muscle diseases such as progressive, Duchenne-type muscular dystrophy. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.

# Concurrence of CDRH, Office of In Vitro Diagnostic and Radiological Health (OIR)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety